Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Novonesis (Novozymes) B's annualized net income for the quarter that ended in Mar. 2026 was €796 Mil. Novonesis (Novozymes) B's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €-226 Mil. Therefore, Novonesis (Novozymes) B's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was Negative Tangible Equity%.
The historical rank and industry rank for Novonesis (Novozymes) B's Return-on-Tangible-Equity or its related term are showing as below:
FRA:NZM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 25.29 Med: 34.54 Max: 43627.49
Current: 43627.49
During the past 13 years, Novonesis (Novozymes) B's highest Return-on-Tangible-Equity was 43,627.49%. The lowest was 25.29%. And the median was 34.54%.
FRA:NZM's Return-on-Tangible-Equity is ranked better than 99.94% of 1570
companies
in the Chemicals industry
Industry Median: 5.77
vs FRA:NZM: 43627.49
Novonesis (Novozymes) B (FRA:NZM) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Novonesis (Novozymes) B Return-on-Tangible-Equity Related Terms
Novonesis (Novozymes) B Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Novonesis (Novozymes) B's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B Return-on-Tangible-Equity Chart
FRA:NZM vs LIN, SHW, ECL: Return-on-Tangible-Equity Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B Return-on-Tangible-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
Novonesis (Novozymes) B (FRA:NZM) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Novonesis (Novozymes) B and its competitors. Over the past decade, Novonesis (Novozymes) B's Return-on-Tangible-Equity has ranged from 25.29 to 43,627.49. According to the industry distribution chart, Novonesis (Novozymes) B ranks #1 out of 1570 companies in the Chemicals industry, placing it in the top 0.099999999999994%.
Is Novonesis (Novozymes) B's Return-on-Tangible-Equity too high?
Novonesis (Novozymes) B's current Return-on-Tangible-Equity is Negative Tangible Equity%. Over the past 10 years, this metric has ranged from a low of 25.29 to a high of 43,627.49. Based on the distribution chart, Novonesis (Novozymes) B ranks #1 out of 1570 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's Return-on-Tangible-Equity compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #1 out of 1570 companies for Return-on-Tangible-Equity. This places Novonesis (Novozymes) B in the top 0% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 5.77. Historically, Novonesis (Novozymes) B's own Return-on-Tangible-Equity has ranged from 25.29 to 43,627.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Chemicals company?
The median Return-on-Tangible-Equity among Chemicals companies is 5.77, based on 1,570 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median Return-on-Tangible-Equity is 5.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (FRA:NZM) is currently considered Fairly Valued. The stock's GF Value™ is €56.81, compared to a current price of €56.50 — trading 0.5% below its estimated fair value. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Novonesis (Novozymes) B (FRA:NZM), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (FRA:NZM) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued.
The current stock price of €56.50 is trading 0.5% below its estimated GF Value™ of €56.81.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
No single metric tells the full story. See the FRA:NZM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score
Get the complete analysis for FRA:NZM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NZM has been successfully added to your 
